NIPPON-KINZOKU
23.7.2024 10:02:34 CEST | Business Wire | Press release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announces that it has named and registered the trademark "Fine Profile" for its cold profile rolled products, which can be used for various metals from ferrous to nonferrous, by combining its proprietary cold rolling technology and specialized equipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723992481/en/
Fine Profile is a generic term for products made by continuously processing ferrous and nonferrous metals into irregularly shaped cross sections with different thicknesses in the width direction using our unique rolling technology. It contributes to customers' process reduction, environmental improvement, manufacturing cost reduction, and yield improvement as an alternative to various processes such as cutting and grinding. (Graphic: Business Wire)
Fine Profile is our original new product that contributes to customers' manufacturing cost reduction and yield improvement as an alternative to various machining processes such as cutting and grinding, and we aim to expand sales of this product in the future.
Features
-
Cost reduction of metal processing, resource saving, energy saving
Use of a deformed cross-sectional shape contributes to reduce machining processes and waste. -
Stabilization of quality
Continuous rolling from coil provides stable supply of high quality products. -
Roll forming on metal surfaces
By rolling the uneven pattern on the roll surface, it is possible to process various designs and functions such as unique designs, oil grooves, gloss prevention, identification grooves, etc. -
Various delivery forms
We can deliver products in a variety of forms, such as record rolls, oscillate rolls, fixed-length products, and secondary processing, etc. according to customer needs. -
Shorter development period
Roll design using CAE analysis contributes to reduction of customers' development cost and time.
Metal types
Nonferrous metals: oxygen-free copper, copper alloys, aluminum alloys, pure titanium, titanium alloys, pure nickel, magnesium alloys, etc.
Stainless steel: SUS304 (L), SUS316 (L), SUS430, SUS420J2, SUS440C, etc.
Carbon steel: SS400, SPCD, SPCC, SPHC, SECC, etc.
Special steel: SCM415, SUJ2, S10C, S45C, S65C, SAE1070, SK75, SK95, SKS81, 1LSSP, etc.
* Please inquire separately for specifications other than those listed above.
Application examples
Fine Profile is developed and manufactured by our rolling technologies and co-creation with our customers that require stable quality and reliability in various applications.
- Automotive applications (Automotive drive parts, Bearing components, Vane pump parts, Engine parts, etc.)
- Electrical and electronic parts applications (Connector parts, Secondary battery terminals, Heat spreaders, Bus bars, etc.)
- Building material applications (Grating components, Braille studs, Screen components, Special fasteners, etc.)
About NIPPON KINZOKU Group
Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723992481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom